Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

At Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Frankfurt, clinical research in musculoskeletal diseases focuses on inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The trials are designed to test new treatment options and measure whether they can better reduce disease activity and improve symptoms.

• Rheumatoid arthritis studies evaluating whether investigational therapies can improve joint inflammation and overall disease control
• Psoriatic arthritis research assessing symptom relief and treatment effectiveness compared with placebo
• Trials aimed at improving outcomes for people with chronic autoimmune joint disease

This area reflects a strong interest in immune-mediated inflammation and in finding better ways to manage long-term joint disease.

Research in skin and connective tissue diseases at this site includes studies in systemic sclerosis, a condition that can affect the skin and internal organs. The work is centered on evaluating whether new therapies can slow disease progression and improve organ-related outcomes.

• Systemic sclerosis trials exploring effects on lung function and broader disease symptoms
• Studies focused on treatment effectiveness for complex connective tissue disease
• Research intended to support better control of disease-related complications

The Fraunhofer-Institut für Translationale Medizin und Pharmakologie contributes to efforts that connect laboratory insight with practical advances for patients living with rare and difficult-to-treat disorders.

The site also conducts trials in immune system processes, with a particular emphasis on autoimmune diseases such as systemic lupus erythematosus. These studies aim to assess whether new medicines can improve signs and symptoms while also supporting longer-term safety.

• Systemic lupus erythematosus research evaluating symptom control and disease activity
• Trials testing whether emerging therapies can offer better immune modulation
• Long-term studies examining ongoing safety in adults with active autoimmune disease

Across these studies, the focus is on autoimmune inflammation and on advancing treatment options for patients with persistent immune-driven disease.